Balaji Prasad
Stock Analyst at Barclays
(3.09)
# 1,236
Out of 4,876 analysts
147
Total ratings
43.9%
Success rate
0.22%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $9.14 | +173.52% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $8.13 | +35.30% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $23.48 | +2.21% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $9.01 | -0.11% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $106.90 | +87.09% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $14.29 | +32.96% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $40.35 | +48.70% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $156.17 | +56.24% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $9.86 | +143.41% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $25.66 | -14.26% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $531.32 | -2.13% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $16.76 | +55.13% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $114.15 | +40.17% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $15.07 | +12.81% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $9.14 | +96.94% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.57 | +180.11% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $0.74 | +842.00% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $9.14
Upside: +173.52%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $8.13
Upside: +35.30%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $23.48
Upside: +2.21%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $9.01
Upside: -0.11%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $106.90
Upside: +87.09%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $14.29
Upside: +32.96%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $40.35
Upside: +48.70%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $156.17
Upside: +56.24%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $9.86
Upside: +143.41%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $25.66
Upside: -14.26%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $531.32
Upside: -2.13%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $16.76
Upside: +55.13%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $114.15
Upside: +40.17%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $15.07
Upside: +12.81%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $9.14
Upside: +96.94%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.57
Upside: +180.11%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $0.74
Upside: +842.00%